P37: Decreased Serum Levels of Interleukin-35 Among Patients with Relapsing Remitting Multiple Sclerosis

Authors

  • Nafiseh Esmaeil Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Navid Manouchehri a. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran b. Students Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Omid Mirmosayyeb a. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran b. Students Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Parisa Soleimani a. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran b. Students Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Shervin Badihian a. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran b. Students Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Vahid Shaygannejad a. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran b. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  • Zahra Samee a. Isfahan Neurosciences Research Center, Alzahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran b. Students Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract:

The regulatory role of interleukin-35 (IL-35) in the immunopathogenesis of multiple sclerosis (MS) is suggested in very few studies. We aimed to measure serum levels of IL-35 among clinically isolated syndrome (CIS) and relapsing-remitting MS (RRMS) patients and evaluate the associations between this cytokine and the disease clinical course. This cross-sectional study was conducted during 2017 in MS Clinic of Kashani hospital, Isfahan, Iran. Forty patients with the diagnosis of CIS and RRMS according to McDonald criteria were included in the study, as well as 40 healthy controls. Also, data regarding clinical course of the disease was collected from cases. The levels of IL-35 in the serum of all subjects were determined by ELISA. Serum levels of IL-35 were comparison with healthy controls. Moreover, the mean serum levels of IL-35 among new cases (diagnosed within 6 months before the study) were decreased compared to healthy controls but it were not statistically significant (P=0.059).The mean serum levels of IL-35 were significantly higher in new cases compared with other cases (p=0.048). We found decreased serum levels of IL-35 among RRMS patients compared to the healthy controls. We provide a view of the possible role of IL-35 in MS pathogenesis and the potential therapeutic targets in this way.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Serum Leptin Levels in Treatment-Naive Patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis

Several studies have investigated leptin levels in patients with multiple sclerosis (MS) with somewhat conflicting results. They have all focused on patients with established relapsing-remitting (RR) MS but have not specifically looked at patients with clinically isolated syndrome (CIS) suggestive of MS, in the early stages of disease. In this study, serum leptin levels were measured in 89 trea...

full text

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis

Introduction: Fingolimod is the first confirmed oral immune-modulator to treat Relapsing-Remitting Multiple Sclerosis (RRMS). This study aimed to investigate the safety and efficacy of fingolimod therapy in Iranian patients with RRMS. Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned to receive fingolimod 0.5 mg per day for 12 months. The number of D...

full text

Increased IL-17A but Decreased IL-27 Serum Levels in Patients with Multiple Sclerosis

Background: Effector CD4+ T cell subsets play an important role in Multiple Sclerosis (MS). Interleukin-27 (IL-27) suppresses Th (Th1, Th2 and Th17) cells and dampens autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory T cells (Tr1). Objective: To identify the relative levels of IL-27 and IL-17A in MS disease. Method: In a case-control study, venous blood was c...

full text

Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis

Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and cytokines may play a role in the development of MS lesions. Objective: To determine levels of different cytokines in patients with relapsing-remitting MS (RR-MS) compared to healthy controls. Methods: Profiles of pro-inflammatory, Th1-, Th2-, and Th17-related cytokines were compared by quantitative ...

full text

Increased Expression of miR-202-3p in Patients with Relapsing-Remitting Multiple Sclerosis

Background and objectives: One of the latest studies in the genetics field is the evaluation of role of micro-RNAs as a biomarker for diagnosis of multiple sclerosis (MS), which is a demyelinating disease of the central nervous system (CNS) and emerges in the form of numerous small and large plaques in white matter in the brain and spinal cord. This disease could be associated with several comp...

full text

Comparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis

Background: The present study aimed to compare the clinical efficacy and safety profile of Ziferon and Betaferon. Objectives: In total, 41 consecutive patients with relapsing forms of Multiple Sclerosis (MS) were selected from the MS outpatient clinic affiliated to Tehran University of Medical Sciences. The patients were randomly assigned into two groups. Methods: Each group either received Z...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 6  issue 2

pages  68- 68

publication date 2018-04

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023